Joseph Therriault

Research interests

Publications

• Plasma p-tau217 and tau-PET predict future cognitive decline among cognitively unimpaired individuals: implications for clinical trials

  Nature Aging · 2025 · 10.1038/s43587-025-00835-z

• Biomarker-based staging of Alzheimer disease: rationale and clinical applications

  Nature Reviews Neurology · 2024 · 10.1038/s41582-024-00942-2

• Diagnosis of Alzheimer’s disease using plasma biomarkers adjusted to clinical probability

  Nature Aging · 2024 · 10.1038/s43587-024-00731-y

• Challenges in the practical implementation of blood biomarkers for Alzheimer’s disease

  The Lancet Healthy Longevity · 2024 · 10.1016/j.lanhl.2024.07.013

• Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology

  JAMA Neurology · 2024 · https://doi.org/10.1001/jamaneurol.2023.5319

• Astrocyte reactivity influences amyloid-β effects on tau pathology in preclinical Alzheimer’s disease

  Nature Medicine · 2023 · 10.1038/s41591-023-02380-x

• A two-step workflow based on plasma p-tau217 to screen for amyloid β positivity with further confirmatory testing only in uncertain cases

  Nature Aging · 2023 · 10.1038/s43587-023-00471-5

• Equivalence of plasma p‐tau217 with cerebrospinal fluid in the diagnosis of Alzheimer's disease

  Alzheimer s & Dementia · 2023 · 10.1002/alz.13026

• Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer's disease

  EBioMedicine · 2022 · 10.1016/j.ebiom.2022.103836

• Biomarker modeling of Alzheimer’s disease using PET-based Braak staging

  Nature Aging · 2022 · 10.1038/s43587-022-00204-0

• Association of Phosphorylated Tau Biomarkers With Amyloid Positron Emission Tomography vs Tau Positron Emission Tomography

  JAMA Neurology · 2022 · 10.1001/jamaneurol.2022.4485

• Astrocyte biomarker signatures of amyloid-β and tau pathologies in Alzheimer’s disease

  Molecular Psychiatry · 2022 · 10.1038/s41380-022-01716-2

• Staging of Alzheimer’s disease: past, present, and future perspectives

  Trends in Molecular Medicine · 2022 · 10.1016/j.molmed.2022.05.008

• Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum

  JAMA Neurology · 2021 · https://doi.org/10.1001/jamaneurol.2021.3671

• Microglial activation and tau propagate jointly across Braak stages

  Nature Medicine · 2021 · https://doi.org/10.1038/s41591-021-01456-w

• Longitudinal 18F-MK-6240 tau tangles accumulation follows Braak stages

  Brain · 2021 · 10.1093/brain/awab248

• Mild behavioral impairment is associated with β‐amyloid but not tau or neurodegeneration in cognitively intact elderly individuals

  Alzheimer s & Dementia · 2020 · 10.1002/alz.12007

• Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts

  The Lancet Neurology · 2020 · https://doi.org/10.1016/s1474-4422(20)30071-5

• Determining Amyloid-β Positivity Using18F-AZD4694 PET Imaging

  Journal of Nuclear Medicine · 2020 · 10.2967/jnumed.120.245209

• Stage-specific links between plasma neurofilament light and imaging biomarkers of Alzheimer’s disease

  Brain · 2020 · 10.1093/brain/awaa342

• 18F-MK-6240 PET for early and late detection of neurofibrillary tangles

  Brain · 2020 · 10.1093/brain/awaa180

• Mild behavioral impairment is associated with β‐amyloid but not tau or neurodegeneration in cognitively intact elderly individuals

  Alzheimer s & Dementia · 2020 · 10.1002/alz.12007

• Mild behavioral impairment is associated with β‐amyloid but not tau or neurodegeneration in cognitively intact elderly individuals

  Alzheimer s & Dementia · 2020 · 10.1002/alz.12007

• APOEε4 potentiates the relationship between amyloid-β and tau pathologies

  Molecular Psychiatry · 2020 · 10.1038/s41380-020-0688-6

• Association of Apolipoprotein E ε4 With Medial Temporal Tau Independent of Amyloid-β

  JAMA Neurology · 2019 · 10.1001/jamaneurol.2019.4421

• In vivo quantification of neurofibrillary tangles with [18F]MK-6240

  Alzheimer s Research & Therapy · 2018 · 10.1186/s13195-018-0402-y

• Monoamine oxidase B inhibitor, selegiline, reduces 18F-THK5351 uptake in the human brain

  Alzheimer s Research & Therapy · 2017 · https://doi.org/10.1186/s13195-017-0253-y

Current projects

No projects listed.